Ahmed Koriesh: Stroke Prevention in the New 2026 ACC/AHA Dyslipidemia Guideline
Ahmed Koriesh, Director of Hospital Neurology Service at Cleveland Clinic Florida, shared on LinkedIn:
”New 2026 ACC/AHA Dyslipidemia Guideline – What Neurologists Should Know
Stroke prevention is one of the areas most affected by the new lipid guidelines.
A few points stood out for neurologists:
- Lower LDL is Better
For patients with established ASCVD (including ischemic stroke), the guideline reinforces aggressive LDL lowering — most stroke patients would qualify for <55 mg/dL target.
- Earlier combination therapy
Rather than waiting months to escalate therapy, the guideline encourages earlier addition of ezetimibe or PCSK9 inhibitors when LDL targets are not reached.
- Lp (a) is gaining attention
Measurement of lipoprotein(a) is now recommended at least once in many patients to better define inherited cardiovascular and stroke risk.
- New lipid therapies are coming
Long-acting therapies targeting PCSK9 and emerging RNA-based treatments will help long-term lipid control in high-risk patients.
For neurologists, the guidelines leans towards more aggressive risk reduction.
For a clinical summary focused on stroke care.”

Stay updated with Hemostasis Today.
-
Jun 14, 2026, 22:49Cihan Ay: From First Oral Presentation to Pro and Con Debate – A 20-Year EHA Journey
-
Jun 14, 2026, 19:54Tareq Abadl: What Happens If You Transfuse the Wrong Blood Group?
-
Jun 14, 2026, 19:46Amber Yates: Stretching Scientific Muscles in Areas of Hematology – Day 2 at EHA 2026
-
Jun 14, 2026, 19:41Peter Loffelhardt: Thousands of People Coming in – Second Day at EHA 2026
-
Jun 14, 2026, 19:38Jecko Thachil: Can We Predict and Prevent Bleeding in APL?
-
Jun 14, 2026, 19:32Highlights from Day 1 at the EHC Leadership Conference 2026
-
Jun 14, 2026, 18:01Ahmar U. Zaidi: The First Pivotal Study of a New Mechanism in Sickle Cell Disease
-
Jun 14, 2026, 18:00Lennart Lenk: Witnessing Former Boss Deliver a Plenary Talk at EHA 2026
-
Jun 14, 2026, 18:00Priya Sriskandarajah: Great Presentations on Recent Advances in Myelofibrosis at EHA 2026